Prof James Catto from the University of Sheffield described the findings as a "major breakthrough" in treating bladder cancer ...

Adding durvalumab and bevacizumab to transarterial chemoembolization improved responses and progression-free survival.

The NRG-HN004 trial showed that durvalumab did not improve outcomes vs cetuximab in locoregionally advanced head and neck ...

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...

In the new study, patients diagnosed with the three main types of bile duct cancer (intrahepatic, perihilar or distal ...

According to Bladder Cancer UK, the main symptoms of bladder cancer are: ...

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...

Durvalumab did not improve outcomes compared with cetuximab in patients with head and neck squamous cell carcinoma who are ...

A phase 3 clinical trial has shown that patients were 32 per cent less likely to experience cancer recurrence when treated ...

A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder ...

Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, ...

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...